In a recent study, Human beta defensin-1 (DEFB1) loss was observed in 95.6% of Gleason 3 and 90% of Gleason 4 biopsies, and it was concluded that DEFB1 loss is a useful indicator to identify patients with high risk of developing prostate cancer (Hong et al., APMIS. 2017 Sep 8). Phigenix is currently developing a DEFB1-based diagnostic test for prostate cancer.